Briacell Therapeutics Corp
BCTXW0.009USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Briacell Therapeutics Corp Info
Ticker SymbolBCTXW
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Ticker SymbolBCTXW
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Company Executives of Briacell Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
--
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
9
94.26K
0.00%
--
2025Q4
9
94.26K
0.00%
-98.94K
2025Q3
10
94.26K
0.00%
-81.79K
2025Q2
12
176.06K
0.00%
+25.38K
2025Q1
10
150.67K
0.00%
-485.33K
2024Q4
9
457.21K
0.00%
-22.64K
2024Q3
9
479.86K
0.00%
+19.04K
2024Q2
9
460.82K
0.00%
+10.02K
2024Q1
10
495.80K
0.00%
-700.81K
2023Q4
9
495.00K
0.00%
-45.14K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Two Sigma Investments, LP
18.26K
0%
-35.23K
-65.86%
Sep 30, 2025
Clear Street LLC
--
0%
-100.00
-100.00%
Jun 30, 2025
Newbridge Financial Services Group, Inc.
1.00K
0%
--
--
Sep 30, 2025
Susquehanna International Group, LLP
--
0%
-16.25K
-100.00%
Jun 30, 2025
Armistice Capital LLC
--
0%
-25.00K
-100.00%
Sep 30, 2025
Redmond Asset Management, LLC
75.00K
0%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
--
0%
-314.00
-100.00%
Sep 30, 2025
Osaic Holdings, Inc.
--
0%
-800.00
-100.00%
Jun 30, 2025
HRT Financial LP
--
0%
-21.25K
-100.00%
Sep 30, 2025
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
